Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
Mem. Inst. Oswaldo Cruz
;
106(supl.1): 202-211, Aug. 2011. tab
Artículo
en Inglés
| LILACS
| ID: lil-597262
ABSTRACT
Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Anticuerpos Antiprotozoarios
/
Malaria Vivax
/
Malaria Falciparum
/
Vacunas contra la Malaria
/
Antígenos de Protozoos
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Mem. Inst. Oswaldo Cruz
Asunto de la revista:
Medicina Tropical
/
Parasitología
Año:
2011
Tipo del documento:
Artículo
/
Documento de proyecto
País de afiliación:
Colombia
/
Estados Unidos
Institución/País de afiliación:
Malaria Vaccine and Drug Development Center/CO
/
Universidad del Valle/CO
/
University of Miami Miller School of Medicine/US
Similares
MEDLINE
...
LILACS
LIS